PORT WASHINGTON, N.Y., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals today announced that Rising Pharmaceuticals Inc, its generic finished dosage form subsidiary, has launched the 250 mg and 500 mg strengths of Disulfirm Tablets, the first approved generic version of Teva's Antabuse Tablets®, following the U.S. Food and Drug Administration (FDA) approval of an Abbreviated New Drug Application (ANDA). According to IMS Health data, U.S. brand sales for Antabuse®, which is used to treat chronic alcoholism, were approximately $19 Million for the twelve months ended December 31, 2010.
ABOUT ACETO
Aceto Corporation, incorporated in 1947, is a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. With business operations in ten countries, Aceto distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. Aceto's global operations, including a staff of 26 in China and 12 in India are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. (ACET-F)
This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in Aceto's reports filed with the Securities and Exchange Commission, including, but not limited to, Aceto's Annual Report or Form 10-K for the fiscal year ended June 30, 2010 and other filings. Copies of these filings are available at http://www.sec.gov/ blocked::http://www.sec.gov/">www.sec.gov. Aceto undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.